PMID: 28494403

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.

Bartlett John M S, Ahmed Ikhlaaq, Regan Meredith M, Sestak Ivana, Mallon Elizabeth A, Dell'Orto Patrizia, Thürlimann Beat, Seynaeve Caroline, Putter Hein, Van de Velde Cornelis J H

European journal of cancer (Oxford, England : 1990) · 2017

Vol. 79, pp. 129-138

View on PubMed DOI

This entry links to third-party literature. For research use only.

AgedAnastrozoleAntineoplastic Agents, HormonalAromatase InhibitorsBreast NeoplasmsChemotherapy, AdjuvantClinical Trials, Phase III as TopicDrug SubstitutionFemaleHumans

For research use only. This index links to third-party literature. Nothing here constitutes medical advice.

HER2 status predicts for upfront AI benefit: A&#xa0;TRANS-AIOG meta-analysis of 12,129 patients from&#xa0;ATAC, BIG 1-98 and TEAM with centrally determined HER2.

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.